Novo Nordisk Patent Loss In India Tests GLP 1 Valuation Story [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) is set to lose its key semaglutide patent protection in India in the near term. Several Indian pharmaceutical companies are preparing lower cost generic versions of semaglutide for the local market. The patent expiry could reshape access to GLP-1 based weight loss and diabetes treatments across a large and price sensitive population. Novo Nordisk is a global pharmaceutical company focused on diabetes, obesity and other chronic diseases, with semaglutide at the center of its GLP-1 treatment portfolio. India is a large market where affordability is critical, so the move from a single branded product to multiple generics could change how patients, doctors and payers approach GLP-1 therapies. For investors, this development adds another data point to the wider GLP-1 story unfolding across different regions and price points. The loss of ex
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- When generic versions of weight-loss drugs arrive, public plans should cover them, experts say [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- FDA: Novo Nordisk failed to report deaths of weight-loss drug patients [USA TODAY]USA TODAY
- Eli Lilly Just Opened the Door to Even Greater GLP-1 Growth [Yahoo! Finance]Yahoo! Finance
- Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk Faces Legal Probe As Trial Setback Reshapes Risk Expectations [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/9/26 - Form 6-K
- 3/2/26 - Form 6-K
- 3/2/26 - Form 6-K
- NVO's page on the SEC website